Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of efficacy and safety of bisphosphonate in hypercalcemia of malignancy finds rate of normalization similar between all bisphosphonates, significantly more hypocalcemia on day 4 with 4 mg zoledronic acid vs. pamidronate.”
Title: Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy
Authors: Sydney E. Schultz, Jason N. Barreto, Kristin C. Cole, Yucai Wang, Grace M. Choong, and Nelson Leung
You can read the Full Article in JCO Oncology Practice.
You can find more posts featuring Robert Orlowski on OncoDaily.
